文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

九旬以上患者地高辛群体药代动力学与给药方案优化

Population Pharmacokinetics of Digoxin in Nonagenarian Patients: Optimization of the Dosing Regimen.
PubMed 文献 · Clin Pharmacokinet · 2023-10-10

本研究在326例90岁以上住院患者中构建地高辛群体药代动力学模型,发现清除率主要受Cockcroft-Gault肌酐清除率、袢利尿剂合用和性别影响,分布容积受血钾影响。基于模型提出九旬患者地高辛剂量调整方程,模型经内部和外部验证,预测性能精确,可用于治疗药物监测。

要点

  • 地高辛清除率主要受Cockcroft-Gault肌酐清除率影响,合用袢利尿剂降低清除率,男性清除率较高。
  • 血钾升高降低地高辛分布容积。
  • 基于模型提出九旬患者剂量调整方程:剂量(mg)=0.144·(CG/36.4)^0.468·0.83^LD·1.21^SEX。

核心结论

  • 地高辛清除率最大影响因素为Cockcroft-Gault方程计算的肾功能,分布容积随血钾升高而降低。
  • 所建模型预测性能精确,可应用于治疗药物监测。

研究设计与样本

  • 回顾性纳入西班牙Severo Ochoa大学医院326例90岁以上接受地高辛治疗药物监测的住院患者。
  • 采用NONMEM软件进行非线性混合效应群体建模,测试一室和二室模型。
  • 通过逐步协变量模型构建筛选协变量,最终模型经1000次bootstrap内部验证,并用95例同特征患者外部验证。

主要发现

  • 人群男性占26%,平均年龄93.2岁(90-103岁),平均肌酐1.11 mg/dL(0.42-3.81 mg/dL),平均总体重61.2 kg(40-100 kg)。
  • 地高辛药代动力学最佳描述为一室模型(ADVAN2 TRANS2),采用交互作用的一阶条件估计法。
  • 影响模型的协变量为Cockcroft-Gault肌酐清除率、血清钾、合用袢利尿剂和性别。
  • 清除率方程:Cl/F = 4.55 · (CG/36.4)^0.468 · 0.83^LD · 1.21^SEX;分布容积方程:Vd/F = 355 · (K/4.3)^-0.849;吸收速率常数Ka = 1.22 h^-1。

关键数值与推荐

  • 剂量调整方程:剂量(mg) = 0.144 · (CG/36.4)^0.468 · 0.83^LD · 1.21^SEX,其中LD表示袢利尿剂(1为使用,0为未用),SEX表示性别(1为男性,0为女性)。

临床怎么用

  • 对90岁以上患者,可根据Cockcroft-Gault肌酐清除率、是否合用袢利尿剂和性别,使用所提方程估算地高辛剂量。
  • 结合血钾水平评估分布容积变化,并利用模型预测性能支持治疗药物监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to develop a population pharmacokinetic model of digoxin in patients over 90 years old and to propose an equation for adjusting digoxin dose in this population. METHODS: We included 326 nonagenarian patients admitted to Severo Ochoa University Hospital (Spain) who received digoxin and were under therapeutic drug monitoring. All data were retrospectively collected, and population modeling was performed with non-linear mixed-effect modeling software (NONMEM®). One- and two-compartment models were tested to calculate digoxin clearance (Cl), volume of distribution (Vd), absorption rate constant (Ka), and bioavailability (bioavailable fraction, F). The covariates were evaluated by stepwise covariate model building, and the final model was internally validated by bootstrap analysis with 1000 resamples. External validation was performed with another population of 95 patients with the same characteristics as the modeling group. RESULTS: The population was 26% males, with a mean age of 93.2 years (90-103 years), mean creatinine 1.11 mg/dL (0.42-3.81 mg/dL), and mean total body weight 61.2 kg (40-100 kg). The pharmacokinetics of digoxin were best described by a one-compartment model (ADVAN2 TRANS2), with first-order conditional estimation with interaction. The covariates with influence on our model were creatinine clearance based on the Cockcroft-Gault equation (CG), serum potassium (K), co-administration of loop diuretics, and sex: Cl/F = 4.55 · (CG/36.4)0.468 · 0.83LD · 1.21SEX; Vd/F = 355 · (K/4.3)-0.849; Ka = 1.22 h-1 [where LD indicates loop diuretics (1 for administered, 0 for otherwise) and SEX indicates patient sex (1 for male, 0 for female)]. Based on our results, we proposed an equation to adjust the digoxin dosing regimen in nonagenarian patients: dose (mg) = 0.144 · (CG/36.4)0.468 · 0.83LD · 1.21SEX. CONCLUSIONS: The greatest influence on digoxin clearance came from renal function calculated by the Cockcroft-Gault equation. Vd was decreased by K. The model developed showed a precise predictive performance to be applied for therapeutic drug monitoring.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Salcedo-Mingoarranz AL, Medellín-Garibay SE, Barcia-Hernández E, et al. Population Pharmacokinetics of Digoxin in Nonagenarian Patients: Optimization of the Dosing Regimen. Clin Pharmacokinet. 2023. PMID: 37816957. doi:10.1007/s40262-023-01313-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。